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Abstract
Amyotrophic lateral sclerosis (ALS) is a fatal degenerative motor neuron disorder of which the progression is influenced by
several disease-modifying factors. Here, we investigated ELP3, a subunit of the elongator complex that modifies tRNA wobble
uridines, as one of such ALS disease modifiers. ELP3 attenuated the axonopathy of a mutant SOD1, as well as of a mutant
C9orf72 ALS zebrafish model. Furthermore, the expression of ELP3 in the SOD1G93A mouse extended the survival and attenu-
ated the denervation in this model. Depletion of ELP3 in vitro reduced the modified tRNA wobble uridine mcm5s2U and
increased abundance of insoluble mutant SOD1, which was reverted by exogenous ELP3 expression. Interestingly, the expres-
sion of ELP3 in the motor cortex of ALS patients was reduced and correlated with mcm5s2U levels. Our results demonstrate
that ELP3 is a modifier of ALS and suggest a link between tRNA modification and neurodegeneration.
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Introduction
Amyotrophic lateral sclerosis (ALS) is an adult motor neuron
disorder characterized by the degeneration of motor neurons in
the spinal cord, brainstem and motor cortex, resulting in muscle
weakness, atrophy and spasticity. It is a progressive disease and
usually fatal within 5 years after the diagnosis. Mutations in a
heterogeneous set of genes, such as C9ORF72, SOD1, TARDBP
and FUS have been identified to cause the familial form that
accounts for 10% of all ALS. Most patients (90%) have now
known family history and are classified as ‘sporadic’. Currently,
there is no cure for ALS (1). The phenotypic heterogeneity of
familial and sporadic ALS (2) suggests the existence of modifiers
that determine disease characteristics such as site and age of
onset, progression rate and duration of disease. It is important
to identify these modifiers as they may be targets for therapeu-
tic intervention, even in the absence of a known cause for ALS.
One such factor is subunit 3 of the elongator complex (ELP3). An
association between genetic variation in ELP3 and sporadic ALS
was revealed in a genome-wide association study (3), and there-
after ELP3 was identified as a modifier of survival in patients
carrying the C9orf72 repeat expansion (4).
ELP3 is the enzymatic core of the elongator complex, com-
prised of six subunits (ELP1-ELP6). Elongator complex promotes
the side chain modification of the wobble uridine base of tRNA
(position U34), a process greatly increasing fidelity and effi-
ciency of translation (5–11). Although modification of U34 is
chemically complex and still incompletely understood (12), it is
known that elongator catalyzes the initial step in the formation
of 5-methoxycarbonylmethyl (mcm5) and 5-carbamoylmethyl
(ncm5), two modifications of the tRNA wobble uridine (5,13). In
yeast, Elp3 is essential for the efficient translation of stress
response transcription factors such as Atf1 and Pcr1. The
absence of Elp3 results in poor expression of these factors and is
lethal after stress (9). Interestingly, overexpression of two
tRNAs (lysine and glutamine) rescues this stress-dependent
phenotype of Elp3-deficient yeast (6,9). In higher order organ-
isms, the absence of ELP3 seems to mainly affect the nervous
system. In Caenorhabditis elegans, elpc-3 deletion abolishes tRNA
uridine modification and affects translation, resulting in lower
levels of neuropeptide and reduction of acetylcholine in the
synaptic cleft (8). In the mouse, ELP3 regulates neuronal migra-
tion and differentiation in the developing cerebral cortex
(14,15). The role of ELP3 in humans is far from understood, but
recessive mutations in subunit 1 (ELP1) cause familial dysauto-
nomia (FD), a severe hereditary sensory and autonomic neuro-
pathy (16). ELP1 is the scaffold subunit of the complex and
whose loss-of-function mutations causing FD severely affect
the assembly of the complex. Accordingly, the level of modified
wobble uridines was found to be reduced in the brain of FD
patients (17).
ELP3 has an N-terminal S-adenosyl-methionine (SAM)
domain and a C-terminal histone acetyltransferease (HAT)
domain. The SAM domain contains an iron-sulfur (Fe-S) cluster
that can cleave SAM to form 50-deoxyadenosine radical and
methionine. It has been shown that the SAM domain, but not
the HAT domain, is required to maintain the integrity of the
yeast elongator complex (18). Deletion of ELP3 is associated with
hypoacetylation of histones H3 and H4 in yeast (19), through
which it is thought to regulate transcription elongation,
although this has been questioned (6,20). In Drosophila, Elp3 ace-
tylates the synaptic protein Bruchpilot, resulting in dysregu-
lated glutamatergic vesicle release (21).
Several findings suggest that ELP3 affects the nervous sys-
tem through a loss-of-function mechanism. In mice, it controls
the production and migration of cortical neurons (14,15,22). In
ALS, the genotype increasing the risk to develop the disease
was associated with lower brain expression levels of ELP3 (23).
In Drosophila, loss-of-function mutations induced aberrant axo-
nal outgrowth and synaptic defects and in zebrafish decrease of
Elp3 expression induced motor axonal abnormalities similar to
those induced by mutant SOD1 and mutant TDP43 (3).
We hypothesized that low ELP3 expression renders motor
neurons vulnerable to neurodegeneration while overexpression
is neuroprotective. In this study, we investigated this hypothe-
sis in humans and in different ALS models (zebrafish and
mouse) and found that overexpression of human ELP3 was
indeed protective in zebrafish models for ALS, an effect for
which the SAM domain is necessary. Furthermore, ELP3 affected
muscle innervation, disease onset and survival in the mutant
SOD1 mouse model for ALS. Lowering ELP3 decreased the levels
of the modified tRNA nucleoside, 5-methoxycarbonylmethyl-2-
thiouridine (mcm5s2U), both in the mouse and in NSC34 cells,
while increasing ELP3 expression restored the levels of this
modified uridine and attenuated mutant SOD1 aggregation in
NSC34 cells. Finally, ELP3 levels were reduced in the motor cor-
tex of ALS patients, which correlated with mcm5s2U levels.
Altogether, our results suggest that ELP3 expression modifies
motor neuron degeneration and may do so by altering tRNA
modification in the central nervous system.
Results
Expression of ELP3 prevents axonopathy in two
zebrafish ALS models
To elucidate the role of ELP3 in ALS, we first studied its effect in
two zebrafish models for ALS: one for mutant C9orf72-induced
ALS (C9ALS) and one for mutant SOD1-associated ALS (SOD1ALS).
Injection of 90x(GGGGCC) repeat RNA, but not of 3x(GGGGCC)
repeat RNA, as well as injection of mutant SOD1 RNA but not of
wild-type RNA in zebrafish embryos induced a motor axonop-
athy, characterized by reduced axonal outgrowth and aberrant
branching, as described before (23,24). Co-expressing human ELP3
RNA significantly prevented the toxic effect of the 90x(GGGGCC)
repeat expansion, as it reduced the outgrowth failure by 63.6%
and the number of affected embryos by 56.7% (Fig. 1A and B).
Likewise, co-expression of ELP3 greatly reduced the toxicity of
mutant SOD1 (SOD1A4V), reducing the outgrowth deficit by 56.8%
and the number of embryos with aberrant branching with 63.5%
(Fig. 1C and D). These results in two different zebrafish models
suggest a protective role for ELP3 in ALS.
Ubiquitous, but not neuronal, overexpression of ELP3
attenuates the ALS-like phenotype in the SOD1G93A
mouse
We next investigated whether a similar protection was seen in a
rodent model for ALS, the SOD1G93A mouse. At symptomatic stage
(post-natal day 140), spinal cord and brain ELP3 expression is
reduced in this model by 30.2% and 20.0%, respectively
(Supplementary Material, Fig. S1A and B). We next determined
ELP3 levels in neurons versus glial cells in the SOD1G93A mouse.
To do so, we laser-capture microdissected spinal motor neurons
and the glia surrounding them in SOD1G93A mice (Supplementary
Material, Fig. S1C and D). We found ELP3 levels to be reduced both
in spinal motor neurons and in glia, by 31.4% and 52.4%,
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respectively, compared to non-transgenic mice. Moreover, ELP3
was less abundant in glia than in neurons both in non-transgenic
mice, 38.5%, and in SOD1G93A mice, 57.5% (Fig. 2A). We then
aimed to increase ELP3 levels in the SOD1G93A mouse by overex-
pressing human ELP3. To this end, we crossed the ELP3 KI mouse
with the CAGG-CreER mouse that ubiquitously expresses the Cre
recombinase (generating the ELP3 KI/CAGG-CreER mouse, herein
designated ELP3 KIGAGG). The ELP3 KIGAGG mouse was then
crossed with the SOD1G93A mouse, generating a triple transgenic
mouse. Induction of human ELP3 expression was successfully
achieved by treatment with tamoxifen at post-natal day 60
(Supplementary Material, Fig. S1E, G and K). The total ELP3 levels
were increased by 1.27-fold to 1.50-fold in the spinal cord and
brain of the ELP3 KIGAGG mouse, respectively (Supplementary
Material, Fig. S1F and J). The levels of endogenous ELP3 and
human SOD1 were not modified by the induction of human ELP3
expression (Supplementary Material, Fig. S1H, I, L and M).
We then evaluated the effect of ubiquitous ELP3 expression
in the SOD1G93A mouse. ELP3 did not affect disease onset
(SOD1G93A/ELP3 KI mean 92.361.8 days; SOD1G93A/ELP3 KIGAGG
mean 97.162.0 days; P¼ 0.1671), but prolonged survival
(SOD1G93A/ELP3 KI mean 152.06 1.8 days; SOD1G93A/ELP3 KIGAGG
mean 160.761.9 days; P¼ 0.006) (Fig. 2B and C). This survival
benefit was associated with a protection of neuromuscular
innervation of the gastrocnemius muscle. Expression of ELP3
reduced the number of denervated neuromuscular junctions
(NMJs) of the gastrocnemius muscle by 23.6% (SOD1G93A/ELP3 KI
78.4%; SOD1G93A/ELP3 KIGAGG 59.9%; P< 0.0001) (Fig. 2D).
Nonetheless, the number of surviving spinal motor neurons at
post-natal day 150 was not affected (Fig. 2E).
In addition, we studied the effect of virally expressed human
ELP3 in the mutant SOD1 mouse. AAV9 viral vector expressing
either ELP3 or GFP was delivered intrathecally in SOD1G93A neo-
nates. We found the AAV9 viral vector to be transduced in the
ventral spinal cord in a non-cell specific manner, targeting both
motor neurons and astrocytes (Supplementary Material, Fig. S2A).
Human ELP3 expression was detected in different tissues, such as
brain, spinal cord and muscle, with variable transduction effi-
ciency (Supplementary Material, Fig. S2B and C). Increasing the
expression of ELP3 delayed disease onset by 12 days (SOD1G93A::
AAV9-GFP mean 98.46 2.6 days; SOD1G93A:: AAV9-ELP3 mean
110.66 3.0 days, P¼ 0.0029) and survival by 12.5 days (SOD1G93A::
AAV9-GFP mean 147.161.6 days; SOD1G93A:: AAV9-ELP3 mean
154.96 2.1 days, P¼ 0.0077) (Supplementary Material, Fig. S2D and
E). Viral transduction with AAV-ELP3 decreased the number of
denervated NMJs of the gastrocnemius muscle (SOD1G93A:: AAV9-
GFP 69.1%; SOD1G93A:: AAV9-ELP3 53.0%, P< 0.0001). Similar to the
results obtained in the SOD1G93A/ELP3 KI mice, the number of sur-
viving spinal motor neurons was not affected (Supplementary
Material, Fig. S2F and G).
Because the mechanism of ALS is known to be non-motor
neuron autonomous, at least in SOD1-related ALS, and because
of our finding that ELP3 levels are affected both in motor neu-
rons and in glia, we wondered whether increasing the ELP3
Figure 1. ELP3 is neuroprotective in two zebrafish ALS models. Effect of human ELP3 in the axonopathy induced by C9orf72-associated repeat RNA (A and B) or
SOD1A4V RNA (C and D), assessed by quantification of motor axon length (A and C) and affected embryos/axonal branching quantification (B and D). Co-injection of
wild-type human ELP3 (ELP3) partially prevents the toxicity induced by either 90x(GGGGCC) RNA or SOD1A4V RNA. 3x(GGGGCC) RNA and SOD1WT were used as con-
trols. Data represent mean6S.E.M., one-way ANOVA (A and C), or mean6 95% CI, logistic regression (B and D). n¼90. ***P< 0.001, **P< 0.01. *P<0.05.
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Figure 2. Overexpression of human ELP3 attenuates the ALS-like phenotype in the SOD1G93A mouse. (A) ELP3 mRNA relative expression in neurons and glia from the
lumbar spinal cord of symptomatic (post-natal day 140) SOD1G93A mice. Levels were reduced by 31% and 52% in neurons and glia, respectively, compared to non-trans-
genic mice. Moreover, ELP3 was less abundant in glia than in neurons: 37.5% in non-transgenic mice and 57.5% in SOD1G93A mice. Data represent mean6S.E.M., one-
way ANOVA, n¼4. ***P<0.001, **P<0.01. (B–E) Effect of ubiquitous tamoxifen-induced expression of human ELP3 in SOD1G93A mice. Tamoxifen was administered at
post-natal day 60. (B) Mean disease onset was not affected by ELP3 expression: SOD1G93A/ELP3 KI 92.36 1.8 days, n¼22 versus SOD1G93A/ELP3 KICAGG 97.16 2.0 days,
n¼19. Data are mean6S.E.M., log-rank test, P¼ 0.1671. (C) Mean survival was significantly prolonged by ELP3 expression: SOD1G93A/ELP3 KI 152.06 1.8 days, n¼ 35 ver-
sus SOD1G93A/ELP3 KICAGG 160.76 1.9 days, n¼19. Data are mean6S.E.M., log-rank test, P¼0.006. (D) Relative quantification of the innervation of NMJs of the
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levels only in motor neurons was sufficient to observe the pro-
tective effect found after ubiquitous expression. We therefore
expressed ELP3 in neurons by the generation of a triple trans-
genic mouse, in which tamoxifen treatment resulted in the
expression of ELP3 in Thy1-mediated CreER expressing neurons
such as motor neurons (herein designated SOD1G93A/ELP3
KIThy1) (Supplementary Material, Fig. S1N–U). Interestingly, this
selective induction of ELP3 expression did not affect disease
onset or survival in the SOD1G93A mouse (Fig. 2F and G), likely
because either the expression of ELP3 in motor neurons alone is
not sufficient (or necessary) to prolong the survival of SOD1G93A
mice, or the motor neuron death process affects the expression
of ELP3 during its induction.
ELP3 deletion is detrimental
We next assessed the effect of reducing ELP3 expression in the
SOD1G93A mouse. To do so, we generated an ELP3 knockout
mouse, using the gene trapping technique (25). We found that
absence of ELP3 is lethal around embryonic day 8, as we did
not find gene-trap homozygous embryos after this stage
(Supplementary Material, Fig. S3, Table S1), confirming that
ELP3 is essential for mammalian embryogenesis, as reported
(26). Reduction of ELP3 expression by 50% (Supplementary
Material, Fig. S3A–C) did not affect embryogenesis or result in
gross abnormalities in adulthood. Constitutive heterozygous
deletion of ELP3 accelerated disease onset (Fig. 3A) (109 days in
SOD1G93A and 102 days in SOD1G93A/ELP3þ/ mice; P¼ 0.0230),
but did not affect survival (Fig. 3B) (157 days in SOD1G93A and
154 days in SOD1G93A/ELP3þ/; P¼ 0.27) in the SOD1G93A mouse.
Motor neuron count and neuromuscular innervation (Fig. 3C
and D) did not differ between the SOD1G93A and SOD1G93A/
ELP3þ/ mice, most likely a reflection of the limited effect size of
reducing ELP3 by only 50%. Unfortunately, we were unable to
evaluate the effect of ELP3 reduction by more than 50% in the
adult SOD1G93A mouse, as both ubiquitous and neuron-specific
conditional knockout of Elp3 in adult mice was rapidly fatal, a
phenotype not affected by the presence of mutant SOD1
(Supplementary Material, Fig. S4). In summary, the hastening of
disease onset due to partial loss of ELP3 in the SOD1G93A mouse
hints for a deleterious effect of ELP3 reduction in this ALS
model. Moreover, these results show that ELP3 is as essential in
the adult organism as it is during development.
The SAM domain mediates the protective effect of ELP3
in the zebrafish
To gain insight into the molecular mechanism of ELP3, we eval-
uated which catalytic domain of ELP3 was mediating its protec-
tive effect. To do so, we mutated the SAM (C109/112S) and the
HAT (Y529A) domains and also deleted the entire HAT domain
(Supplementary Material, Fig. S5A and B), to generate proteins
with reduced or no enzymatic activity (27–29). We tested the
protective effect of these constructs in the C9ALS and
the SOD1A4V zebrafish models. ELP3 lacking the HAT domain
(ELP3DHAT) prevented the motor axonopathy to the same extent
as the full-length ELP3 (Fig. 4), as well as the ELP3Y529A mutant
(Supplementary Material, Fig. S5D). In contrast, ELP3 in which
the SAM domain was inactivated (ELP3SAM) lost its protective
activity in both models (Fig. 4).
As expected, the axonopathy induced by knockdown of ELP3
in zebrafish (3) could also be prevented by ELP3 overexpression
(Supplementary Material, Fig. S5C). Of note, the SAM domain
was necessary for this effect as well, as it was lost for ELP3 lack-
ing an active SAM domain, but not for ELP3 lacking an active
HAT domain (Supplementary Material, Fig. S5C). These results
demonstrate that in this zebrafish model, the SAM domain, but
not the HAT domain, is necessary for the protective effect of
ELP3.
ELP3 regulates wobble mcm5s2U tRNAmodification and
affects mutant SOD1 aggregation in vitro
The modification of the wobble uridine in tRNA is the main func-
tion of ELP3. In FD, a disease caused by loss-of-function muta-
tions in ELP1 resulting in loss of activity of the elongator complex
in the nervous system, the mcm5s2U modification of tRNA is
reduced (17). Interestingly, ablation of ELP3 in yeast and mice
impaired proteome integrity and increases protein aggregation,
by affecting codon translation rates due to defective wobble
mcm5s2U tRNA modification (15,30). To gain insight into the
molecular mechanism underlying the protective effect of ELP3 in
ALS, we investigated the relation between ELP3 expression, wob-
ble uridine modification and protein aggregation.
We first examined the effect of ELP3 depletion on mcm5s2U
levels. In NSC34 cells, reduction of ELP3 expression by 83% dramat-
ically decreased the levels of mcm5s2U by 60% (Fig. 5A and B). In
the mouse, the lethal reduction of ELP3 levels by 90% [tamoxifen-
treated ELP3lox/lox/CAGGCreER (KO) mice] reduced mcm5s2U levels in
the spinal cord and brain by 72% and 75%, respectively, compared
to control mice (Fig. 5C and D; Supplementary Material, Fig. S6A
and B). These results confirm that ELP3 regulates the mcm5s2U
wobble modification of tRNA in vitro and in vivo. In the wild-type
mouse, the pool of tRNAs that should have this modification
appears to be already fully modified, as conditional ubiquitous
expression of human ELP3 did not increase the levels of mcm5s2U
any further (Supplementary Material, Fig. S6C and D).
We next evaluated the effect of ELP3 depletion on protein
aggregation. Silencing ELP3 in NSC34 cells increased the total
amount of aggregating proteins by 28% (Supplementary
Material, Fig. S7A and B). Moreover, it induced an increase of
insoluble mutant human SOD1 (SOD1A4VA, 73.7%; SOD1G93A,
93.2%), but not of wild-type human SOD1 (Fig. 5E–G). In these
conditions, exogenous expression of human ELP3 significantly
reduced the amount of insoluble SOD1G93A to levels similar to
control (Fig. 5H–J) and, concomitantly, it restored the levels of
mcm5s2U by 45.5% (Fig. 5K). These results suggest that the pro-
tective effect of ELP3 in ALS may at least in part be mediated by
affecting mutant SOD1 solubility through an effect on wobble
mcm5s2U tRNA modification.
gastrocnemius muscle in symptomatic mice (post-natal day 150). Denervated NMJs were decreased by ELP3 expression: SOD1G93A/ELP3 KI 78.46 1.0%, n¼3 versus
SOD1G93A/ELP3 KICAGG 59.96 2.7%, n¼3. Data represent mean6S.E.M., one-way ANOVA, P¼0.001. (E) Quantification of ventral horn lumbar motor neurons, in function
of the cell body area, in symptomatic mice (post-natal day 150). No differences were found between genotypes. Data represent mean6S.E.M., two-way ANOVA, n¼3,
P>0.5. (F, G) Effect of neuronal-specific tamoxifen-induced expression of ELP3 in SOD1G93A mice. Tamoxifen was administered at post-natal day 60. (F) Mean disease
onset was not affected by ELP3 expression: SOD1G93A/ELP3 KI 89.16 3.7 days, n¼15 versus SOD1G93A/ELP3 KIThy1 94.26 1.9 days, n¼28. Data are mean6S.E.M., log-rank
test, P¼0.383. (G) Mean survival was not affected by ELP3 expression: SOD1G93A/ELP3 KI 149.06 2.4 days, n¼13 versus SOD1G93A/ELP3 KIThy1 149.161.8 days, n¼18.
Data are mean6S.E.M., log-rank test, P¼0.982.
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ELP3 levels correlate with tRNAmcm5s2U levels in the
motor cortex of sporadic ALS patients
To investigate whether the levels of ELP3 and mcm5s2U tRNA
are affected in ALS patients, we quantified the ELP3 mRNA in
the motor cortex and the occipital cortex of sporadic ALS
patients and compared it to controls. ELP3 expression was sig-
nificantly reduced in the motor cortex, but not in the occipital
cortex (Fig. 6A, Supplementary Material, Fig. S7C), a reduction
that correlated with the levels of mcm5s2U, although mcm5s2U
levels in sporadic ALS patients were not altered compared to
controls (Fig. 6B and C). Together, these results suggest that
ELP3 may act as a modifier of ALS through influencing tRNA
modifications.
Discussion
Loss of ELP3/elongator complex function is associated with det-
rimental phenotypes in yeast, fly, zebrafish, mice and humans
(3,12,15). We therefore hypothesized that restoring ELP3 levels
may be protective in neurodegeneration. We found ELP3 to be
protective in two zebrafish ALS models, as well as in the
SOD1G93A mouse. In the zebrafish, expression of human ELP3
prevented the toxicity induced by both SOD1A4V expression and
90x(GGGGCC) RNA, a novel zebrafish model for C9orf72 ALS.
This result prompted us to investigate the role of ELP3 in the
SOD1G93A mouse, in which we found the expression of ELP3 to
be reduced in the brain and spinal cord. We expressed human
ELP3 ubiquitously in pre-symptomatic (post-natal day 60) mice
and found the survival to be moderately increased. The fact
that the total expression of ELP3 after ubiquitous induction of
human ELP3 was also moderately increased (not more than 1.5-
fold of the endogenous ELP3 expression) underscores the biolog-
ical relevance of these results.
A similar effect on survival was observed when human ELP3
was expressed in SOD1G93A neonates after intrathecal delivery of
AAV9 viral vectors, although this effect was largely due to its
effect on disease onset. The explanation for this effect on onset
versus disease duration is unclear, although the difference
between transgenic expression at post-natal day 60 versus viral
expression at post-natal day 1 is likely to contribute to it.
Nevertheless, these two approaches suggest that ELP3 expression
in the SOD1G93A mouse is protective both in the pre-symptomatic
stage and in the symptomatic stage. The expression of ELP3 in
the SOD1G93A mouse was also associated with less denervated
NMJs of the gastrocnemius muscle, compared to control mice.
Together with the fact that the number of spinal motor neurons
was unaffected, it suggests that ELP3 exerts its protective effect
through maintaining axon integrity, more so than through main-
taining motor neuron survival, and highlight the role of the NMJs
as the main factor of progression and severity in ALS (31).These
results are consistent with the findings from Gould et al., which
dissociate motor dysfunction from motor neuron death (32).
Ablation of Bax, a pro-apoptotic gene, in the SOD1G93A mouse,
remarkably preserved almost completely the spinal motor neu-
rons, but had limited effect in the reduction of the denervated
NMJs and in increasing survival (32).
Moreover, we found that increasing ELP3 expression specifi-
cally in neurons in pre-symptomatic SOD1G93A mice, per se, was
not sufficient to prolong their survival, suggesting a role for glial
Figure 3. Effect of heterozygous deletion of the ELP3 gene in the SOD1G93A mouse. (A) Mean disease onset was reduced by ELP3 heterozygous deletion: SOD1G93A/
ELP3þ/þ 105.86 2.1 days, n¼45 versus SOD1G93A/ELP3þ/ 98.76 2.2 days, n¼40. Data are mean6S.E.M., log-rank test, P¼0.0141. (B) Mean survival was not affected:
SOD1G93A/ELP3þ/þ 157.56 1.6 days, n¼38 versus SOD1G93A/ELP3þ/ 155.26 1.5 days, n¼30. Data are mean6S.E.M., log-rank test, P¼0.2307. (C) Relative quantification of
the innervation of NMJs of the gastrocnemius muscle in symptomatic mice (post-natal day 104). Denervated NMJs were not affected: SOD1G93A/ELP3þ/þ 43.763.5%,
n¼6 versus SOD1G93A/ELP3þ/ 40.76 10.4%, n¼3. Data represent mean6S.E.M., two-way ANOVA, P¼ 0.9173. (D) Quantification of ventral horn lumbar motor neurons,
in function of the cell body area, in symptomatic mice (post-natal day 104). No differences were found between genotypes. Data represent mean6S.E.M., two-way
ANOVA, n¼ 3, P>0.5.
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cells in the protective effect of ELP3. In agreement, the expres-
sion of ELP3 was reduced in SOD1G93A mice not only in spinal
motor neurons, but, and to a larger extent, also in the glia sur-
rounding them in which expression was reduced by more than
50%. We therefore hypothesize that increasing ELP3 expression
in one or more cell types present in the glia would be protective
in the SOD1G93A mouse, realizing that it is possible that the
selective expression of ELP3 in either astrocytes, microglia or
oligodendrocytes may not be sufficient to see the protective
effect, but that a combined expression of ELP3 in different cell
types is required. This is concurrent with the protective effect
observed after AAV9-mediated ELP3 expression in the SOD1G93A
mouse, as AAV9 viral vectors transduced nonspecifically motor
neurons and glia in the spinal cord.
To confirm the role of ELP3 in neurodegeneration, we also
investigated the effect of ELP3 depletion. We hypothesized that if
low levels of ELP3 were associated with neurodegeneration in the
fish, fly and humans (3), a reduction of ELP3 levels would exacer-
bate the phenotype of the SOD1G93A mouse. Heterozygous dele-
tion of ELP3 did worsen SOD1G93A mouse phenotype, although to
a limited extent. Homozygous deletion of ELP3 was embryonically
lethal, as also observed when other members of the elongator
complex are genetically ablated (16,26). In an attempt to bypass
this lethality, we generated a conditional knockout mouse to
delete ELP3 in adult mice. Interestingly, homozygous ubiquitous
ELP3 deletion was very rapidly lethal in adult mice. Moreover,
selective neuronal ELP3 depletion in the adult mouse was equally
rapidly fatal and was accompanied by a severe neurological phe-
notype (Supplementary Material, Fig. S4). The Thy1CreER mouse
used in this study, the SLICK-H mouse, displays strong and wide-
spread Cre recombination in the cortex, cerebellum, hippocam-
pus and spinal motor neurons (about 90%, data not shown) (33).
Of note, several reports confirm the depletion of an elongator
complex gene from a tissue/organ to be deleterious, with differ-
ent outcomes (14,15,22,34,35). This rapidly progressive phenotype
made the study of the effect of ELP3 reduction by more than 50%
in the SOD1G93A mouse not feasible. Overall, our data confirm
that ELP3 is an essential gene, both in mouse embryos and adult
mice.
The molecular mechanism of the protective effect of ELP3 in
ALS models was further investigated. ELP3 is the catalytic subu-
nit of the elongator complex. In a recent study, it has been
shown that defective wobble uridine tRNA modification results
in slower codon translation rates which impair the proteasome,
thus increasing protein aggregation (30). It is known that ELP3
plays a major role in this modification process (12). In agree-
ment, we found that the levels of the mcm5s2U tRNA modifica-
tion were largely reduced after depletion of ELP3 not only in
NSC34 cells, but also in mice. Moreover, we found protein aggre-
gation to be increased upon ELP3 ablation in NSC34 cells, simi-
larly to yeast (30). Importantly, ELP3 depletion from NSC34 cells
increased the amount of insoluble mutant SOD1, but not of
Figure 4. SAM domain, not HAT domain, mediates ELP3 protective effect in the zebrafish. Effect of ELP3 mutants in the axonopathy induced by C9orf72-associated
repeat RNA (A and B) or SOD1A4V RNA (C and D), assessed by quantification of motor axon length (A and C) and affected embryos/axonal branching quantification
(B and D). Deletion of the HAT domain (ELP3DHAT) does not affect the protective effect of ELP3 (dashed lines), whereas mutation of the SAM domain (ELP3SAM) abolishes
the protective effect of ELP3. 3x(GGGGCC) RNA and SOD1WT were used as controls. Data represent mean6S.E.M., one-way ANOVA (A and C) or mean6 95% CI, logistic
regression (B and D). n  45. ***P<0.001, **P<0.01, *P<0.05.
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Figure 5. Effect of ELP3 expression levels on wobble mcm5s2U tRNA modification and protein aggregation. (A) ELP3 mRNA relative expression in NSC34 cells, 72 h post-
transfection. Levels of ELP3 were reduced by 85.06 2.2% in cells transfected with ELP3-siRNA, compared to control cells. Data represent mean6S.E.M., unpaired t-test,
n¼5. ***P<0.001. (B) mcm5s2U levels in NSC34 cells were reduced by 60.16 2.1% in cells transfected with ELP3-siRNA, compared to control cells. t6A was used as
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wild-type SOD1. Remarkably, the effects of ELP3 depletion on
mcm5s2U levels and protein aggregation in NSC34 cells were
reverted by overexpressing human ELP3. Although the levels
were not fully restored to control, likely due to imbalance of the
elongator complex, they clearly implicate ELP3 in protein aggre-
gation possibly through regulation of mcm5s2U tRNA
modifications.
There are two catalytic domains in ELP3, the SAM and the
HAT domain. Loss-of-function mutations in the SAM domain
not only directly impair the catalytic activity of ELP3, but also
compromise the integrity of the yeast elongator complex (18).
We found that the SAM domain was necessary for the protec-
tive effect of ELP3 in the fish, and that this effect was completely
independent of the HAT domain. This was unexpected as, in
yeast, loss-of-function mutations in both domains of ELP3
equally affect the formation of modified wobble tRNA uredines
(29). Our data suggest that at least in fish, the HAT domain is
not necessary for the observed neuroprotective function of
ELP3/elongator complex.
We next checked the levels of ELP3 and modified tRNA uri-
dines in sporadic ALS patients. We found ELP3 to be reduced in
the motor cortex of sALS patients, but not in the occipital cortex.
Interestingly, the mcm5s2U levels correlated with ELP3 levels,
indicating that mcm5s2U tRNA modifications may contribute to
the pathogenesis of ALS.
Proteasome impairment is considered as one of the patho-
genic factors at play in ALS. It can be triggered by different
mechanisms, ER stress and a heat-shock response amongst
others, resulting in the aggregation of susceptible proteins, such
as SOD1, TDP43 and FUS (36). It is known that defective wobble
mcm5s2U modification reduces the speed of codon translation
rates (15,30), which in turn triggers proteome impairment (30).
Therefore, we propose that ELP3 modifies the pathogenesis of
ALS, by affecting the aggregation of susceptible proteins,
through control of mcm5s2U wobble tRNA modification. Our
data suggest an unexpected link between tRNA modification
and motor neuron degeneration.
Materials and Methods
Plasmids, morpholinos and in vitro RNA transcription
The plasmid encoding human ELP3-FLAG under the control of a
T7 promoter was purchased from Origene (Rockville, MD). The
plasmids encoding ELP3 SAM (C109/112S) and ELP3 HAT (Y529A)
were generated from the human ELP3-FLAG plasmid with
QuickChange II Site-Directed Mutagenesis Kit (Agilent
Technologies, Santa Clara, CA). To generate the ELP3 DHAT vec-
tor, the human ELP3-FLAG plasmid was digested with XhoI
(Thermo Fisher Scientific, Waltham, MA) and the resulting frag-
ment subcloned into the XhoI-digested pCMV6-Entry vector,
under control of a T7 promoter (Origene). To generate the AAV:
ELP3-FLAG transfer plasmid, the human ELP3-FLAG plasmid was
PCR-amplified with the primers 50 CGTGCTCTAGAATGAGGCAG
AAGCGGAAAGGAG and 50 GGTACGTGACTAGTGCCGGCCGTTTA
AACCTTATCG and the resulting product ligated into XbaI/SpeI
(Thermo) digested AAV transfer plasmid (pZac 2.1 eGFP3 SEED).
Human cDNA of SOD1WT, SOD1A4V and SOD1G93A in the pCLneo
vector were kind gifts from R.H. Brown Jr (Harvard Medical
School, Harvard, MA). SOD1 was cloned in the pBCM vector under
control of a T3 promoter. The p90HNR construct to generate the
90 GGGGCC repeat RNA fragment was obtained as described
(24). To synthesize RNA, all plasmids were linearized by restric-
tion digestion, transcribed with the mMESSAGE mMACHINEVR T7
or T3 kit (Ambion, Huntingdon, UK) and the resulting RNA puri-
fied with the MEGAclearTM Kit (Ambion). RNA concentration was
determined by spectrophotometry (Nanodrop, Thermo). The anti-
sense morpholino (Mo) against the start codon (ELP3-Mo; 50-
TGGCTTTCCCATCTTAGACACAATC-30) of zebrafish ELP3 and
the non-targeting control morpholino (Ctrl-Mo; 50-CCTCTTAC
internal control. Data represent mean6S.E.M., unpaired ttest, n¼4. ***P<0.001. (B0) Representative mcm5s2U chromatograms of the conditions analyzed in B. (C) ELP3
mRNA relative expression in spinal cord after ubiquitous tamoxifen-induced deletion of endogenous ELP3 (ELP3lox/lox/CAGGCreER mouse, designated ELP3 KO). Levels
were reduced by 91.56 3.9%. Data represent mean6S.E.M., unpaired t-test, n¼3. ***P<0.001. (D) mcm5s2U levels in spinal cord after ubiquitous tamoxifen-induced
deletion of endogenous ELP3. Levels were reduced by 72.261.7%. t6A was used as internal control. Data represent mean6S.E.M., unpaired t-test, n¼3. ***P<0.001. (D0)
Representative mcm5s2U chromatograms of the conditions analyzed in (D). (E–J) Western blot analyses and quantification of SOD1 protein in detergent-insoluble and
detergent-soluble fractions of NSC34 cells. (E–G) Aggregates of mutant SOD1 (G93A and A4V) accumulate upon siRNA-mediated depletion of ELP3, compared to control
(control-siRNA, –). GAPDH was used as loading control. Data represent mean6S.E.M., one-way ANOVA, n  4. **P<0.01, *P<0.05. (H–J) ELP3 overexpression reduces the
accumulation of SOD1G93A aggregates induced by ELP3 depletion. FLAG was used to control ELP3 overexpression, GAPDH was used as loading control. Data represent
mean6S.E.M., one-way ANOVA, n¼3. ***P<0.001, **P<0.01, *P<0.05. (K) Effect of ELP3 overexpression on the levels of mcm5s2U in NSC34 cells expressing SOD1G93A
and either ELP3-siRNA or control-siRNA. Data represent mean6S.E.M., one-way ANOVA, n¼4. *P<0.05. (K0) Representative mcm5s2U chromatograms of the conditions
analyzed in (K). ***P<0.001, **P<0.01, *P<0.05.
Figure 6. ELP3 expression correlates with wobble mcm5s2U tRNA modification in sALS patients. (A) ELP3 mRNA relative expression in the motor cortex from sALS
patients. Data represent mean6S.E.M., unpaired t-test, n¼8. *P<0.05. (B) mcm5s2U levels in the motor cortex from sALS patients. Data represent mean6S.E.M.,
unpaired t-test, n 6. P> 0.05. (C) Levels of ELP3 mRNA correlate with mcm5s2U levels. Linear regression, n¼9, P¼0.0142.
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CTCAGTTACAATTTATA-30) were designed and obtained from
Gene Tools (Philomath, OR).
rAAV production
Recombinant adeno-associated virus (rAAV) production was
performed by the Neurobiology and Gene Therapy laboratory
(Katholieke Universiteit Leuven, Belgium) as described (37). The
plasmids used were the construct for the AAV2/9 serotype, the
pAdvDeltaF6 adenoviral helper plasmid and the AAV transfer
plasmid, encoding either human ELP3 (AAV: ELP3-FLAG) or eGFP
(AAV: eGFP) under control of the cytomegalovirus (CMV) pro-
moter. Genomic copy number (GC/ml) was determined by qPCR.
Animals
Adult zebrafish (AB strain) and embryos were maintained and
staged under standard laboratory conditions (38). For the intra-
thecal delivery of rAAV vectors, mice neonates (P0.5) were cry-
oanesthetized and immobilized on a styrofoam board. A total of
1  1010 GC of rAAV vectors were injected in the spinal canal at
the lumbar level, as reported previously (39,40), with a 32G
Hamilton syringe (Hamilton, Reno, NV). The maximum volume
injected was 7 ml. The dye lissamine green (Sigma, ST. Louis,
MO) was added to the rAAV vectors at a final concentration of
0.05% (w/v) in PBS to assess delivery accuracy. The procedure
was considered successful when the rAAV vectors diffused
along the spinal tract into the cerebellum/brain, and only neo-
nates successfully injected were considered for this study. The
human ELP3 conditional overexpressing mouse was generated
by Ozgene (Perth, Australia). In brief, ELP3-FLAG cDNA preceded
by a loxP site flanked stop cassette was inserted in the ROSA26
locus by homologous recombination (designated ELP3 KI
mouse). The Elp3 conditional knockout mouse (designated
ELP3lox/lox mouse) was generated by insertion of loxP sequences
flanking the exon 2 of Elp3 (15). The SIGTR embryonic stem cell
line AQ0461 (Mutant Mouse Recourse and Research Center,
USA), containing a gene-trap cassette at intron 1 of the Elp3
gene, was used to generate the constitutive ELP3 knockout
mouse. Genotyping of the constitutive ELP3 knockout mice gen-
erated by heterozygous pairings was performed using the fol-
lowing primers: TRAP cassette, 50 TTA TCG ATG AGC GTG GTG
GTT ATG C and 50 GCG CGT ACATCG GGC AAA TAA TATC; Elp3
exon 1–3, 50 TGAGGCAAAAGAGGAAAGGGGAC; 50 CGGAGTCAGG
TCCTCCGGGGC. Heterozygous mice were backcrossed for eight
generations into a C57BL/6J background. The human mutant
SOD1 overexpressing mouse [B6.Cg-Tg(SOD1*G93A)1Gur/J stock
number 004435], the human wild-type SOD1 over-expressing
mouse [B6.Cg-Tg(SOD1)2Gur/J stock number 002298], the CAGG-
CreER mouse [B6.Cg-Tg(CAG-cre/Esr1*)5Amc/J stock number
004682] and the Thy1-CreER-EYFP mouse (SLICK-H) [Tg(Thy1-
cre/ERT2,-EYFP)HGfng/PyngJ stock number 012708] were pur-
chased from the Jackson Laboratory (Ben Harbor, ME). To induce
Cre-mediated recombination, mice were treated with tamoxifen
(200 mg/kg/day) by oral gavage for four consecutive days. The
PaGE (Paw Grip Endurance) test was used to determine disease
onset by assessing the ability of the mice to hold their own
weight for 60 s. In brief, the mice are placed on a wire grid, 50
cm above the platform, and turned over while hanging upside–
down. When a mouse fails (drops from the grid before 60 s) and
in consecutive trials cannot hold its own weight for 60 s, it is
defined as symptomatic. End stage, used as a measurement of
survival, was defined as the age at which mice could no longer
right themselves within 30 s when placed on their back. Mice
phenotypic analyses were performed in a blinded fashion. Mice
were euthanized at end stage, as it corresponds to the human
end-point. All mice were on a C57BL/6 background. Mice were
housed in standard conditions in the specific-pathogen-free
housing facility of the University of Leuven with food and water
ad libitum. Experiments were performed according to the guide-
lines of the University of Leuven and have received ethical com-
mittee approval (project codes 230/2013, 237/2013, 125/2014 and
126/2014).
Zebrafish staining
Zebrafish work was performed as described previously (23).
Briefly, 1–2 cell stage zebrafish embryos were injected with 1.76
nl of morpholino or in vitro transcribed RNA: 3x(GGGGCC), 318
pg; 90x(GGGGCC), 318 pg; SOD1WT, 1.76 ng; SOD1A4V, 1.76 ng;
ELP3WT, 176 pg; ELP3DHAT, 176 pg; ELP3SAM, 176 pg; ELP3Y529A, 176
pg; ELP3-Mo, 6 ng; Ctrl-Mo, 6 ng. A GFP-encoding RNA was used
as control when morpholinos were not injected. For whole
mount staining, morphologically normal fish were dechorio-
nated, deyolked and fixed at 30 h post fertilization (hpf) in 4%
formaldehyde in phosphate-buffered saline (PBS) overnight at
4˚C. Fish were permeabilized with acetone for 1 h at 20˚C,
blocked with 1%BSA/1%DMSO/PBS for 1 h at room temperature
and immunostained with mouse anti-SV2 (1: 200;
Developmental Studies Hybridoma Bank, University of Iowa,
Iowa City, IA) and secondary Alexa Fluor 555 anti-mouse anti-
body (1: 500; Molecular Probes, Eugene, OR). Axonal length and
axonal branching of motor neurons were quantified as
described previously (23) using Lucia software (version 4.60,
Laboratory Imaging, Prague, Czech Republic). A minimum of 15
fish per condition was analyzed per experiment.
Histological analyses
To visualize NMJs, mice were deeply anesthetized with
Nembutal 10%, the gastrocnemius muscle dissected and snap
frozen in liquid nitrogen-cooled isopentane. Longitudinal cryo-
sections of 20 mm (Slee cryostat, Mainz, Germany) were fixed
with 4% formaldehyde (FA) in PBS for 10 min at room tempera-
ture, blocked with 10% normal donkey serum (Sigma) in PBS-
0.1% Triton X-100 (PBS-T) for 1 h at room temperature and
immunostained with rabbit anti-NF-200 (1:200, # N4142, Sigma)
for 16 h at 4˚C, followed by 1 h incubation at room temperature
with Alexa 555 conjugated a-bungarotoxin (1: 500, # B35451
Invitrogen) and anti-rabbit Alexa 488. NMJs were counted from
five sections for each muscle, using a Zeiss Imager M1 micro-
scope and an AxioCam Mrc5 camera (Carl Zeiss, Oberkochen,
Germany).
To visualize spinal cord neurons, mice were anesthetized
with Nembutal 10%, transcardially perfused with PBS and sub-
sequently with 4% FA in PBS. The lumbar spinal cord was dis-
sected, fixed with 4% FA for 16 h at 4˚C, dehydrated in 30%
sucrose and snap frozen in liquid nitrogen-cooled isopentane.
Two methods were followed. To measure spinal cord neurons,
cross cryosections of 20 mm were stained with cresyl violet
(Sigma), followed by immersion in a 70% ethanol/10% acetic
acid solution and dehydration in an increased ethanol concen-
tration series. Sections were then mounted with PerTexVR
(Histolab AB, Goteborg, Sweden) and neurons visualized with a
Zeiss Imager M1 microscope. Images were obtained with an
AxioCam Mrc5 camera (Carl Zeiss) and the soma area of normal
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appearing neurons in the ventral horn of the spinal cord was
measured with the AxioVision 4.8 software (Carl Zeiss). Every
10th section for a total of 10 sections were analyzed per animal.
To immunolabel spinal cord neurons, cross cryosections of 20
mm were blocked with 10% normal donkey serum in PBS-T for 1
h at room temperature and immunostained with rabbit anti-
Choline acetyltransferase (ChaT, 1: 500) (#AB144P, Millipore) for
16 h at 4˚C, followed by 1 h incubation at room temperature
with anti-rabbit Alexa 488. Slides were mounted using ProLong
Gold antifade reagent with DAPI (Thermo). Images were
obtained using a Zeiss Imager M1 microscope and an AxioCam
Mrc5 camera. For pathological analysis, mice were euthanized
by CO2 asphyxiation followed by complete pathological exami-
nation as described previously (41). Briefly, samples were
immersion fixed in 10% neutral buffered formalin (Sigma), rou-
tinely processed for paraffin embedding, sectioned at 5 lm and
stained with Hematoxylin (Diapath, Martinengo, Italy) and
Eosin (Diapath). Head and sternum were decalcified in a 14%
solution of tetrasodium EDTA for 15 days before processing and
paraffin embedding.
Laser capture microdissection
To microdissect spinal cord neurons, five non-transgenic and
five SOD1G93A mice were anesthetized with Nembutal 10% and
the lumbar spinal cord was dissected and embedded in optimal
cutting temperature (OCT) compound. Cross cryosections of 20
mm, collected on 1.0 PEN slides (Zeiss), were stained with cresyl
violet as described above. Per spinal cord, a total of 1500 motor
neurons from the ventral horn, and the surrounding glia, were
microdissected (PALM RoboSoftware, Zeiss) and collected in
Adhesive Cap 500 opaque tubes (Zeiss).
Gene expression analyses
Total RNA was extracted with Trizol (Thermo) and precipitated
with isopropyl alcohol according to the manufacturer’s instruc-
tions. cDNA was synthesized from 1 lg of total RNA with
SuperScript III Reverse transcriptase (Thermo) and random hex-
amer primers, according to the manufacturer’s instructions.
Quantitative PCR was performed by the StepOnePlusTM (Life
Technologies) with TaqManVR Fast Universal PCR Master Mix
(Life Technologies). Relative gene expression was determined
by the 2DDct method and normalized to the average of the
control group. Graphs represent the relative gene expression as
calculated by the Polr2a expression. Determining relative
expression by G6pdx or GAPDH confirmed the differences
between the genotypes as detected with Polr2a. Digital droplet
PCR was performed following Bio-Rad guidelines (Bio-Rad,
Hercules, CA), using ddPCR Supermix (without dUTPs) for
probes. Droplets were generated in a QX200 Droplet Generator
and scanned with a QX200 Droplet Reader (Bio-Rad). Results
were analyzed with QuantaSoft software from Bio-Rad. Gene
expression assays were purchased from Life Technologies:
Human ELP3, Hs00216429_m1 and Hs00986853_m1; mouse ELP3,
Mm00804538_m1; Human SOD1, Hs00533490_m1; mouse Chat,
Mm01221880_m1; mouse Slc1a2, Mm01275814_m1; Human
PolR2a, Hs00172187_m1; mouse PolR2a, Mm00839502_m1,
Human GAPDH, Hs99999905_m1 and mouse G6pdx,
Mm00656735_g1. The Polr2a-HEX labeled Taqman assay
Mm.PT.58.13811327 for the digital droplet PCR was from inte-
grated DNA Technologies (Leuven, Belgium).
HPLC and UPLC quantification of tRNAmodified
uridines
Total RNA was extracted from tissue with Trizol and precipitated
with isopropyl alcohol according to the manufacturer’s instruc-
tions. Total tRNA was isolated using Nucleobond RNA/DNA 80
columns (Macherey-Nagel, Du¨ren, Germany) and precipitated
with isopropyl alcohol. Total tRNA was digested to nucleosides
using nuclease P1 (Sigma) and bacterial alkaline phosphatase
(Sigma) and analyzed as described earlier (42). t6A was used as
internal control to normalize mcm5s2U quantification.
Cell culture and transfections
NSC34 cells (Mouse Motor Neuron-Like Hybrid Cell Line,
Cedarlane Laboratories, Ontario, Canada) were cultured in high
glucose DMEM (Invitrogen) supplemented with 10% fetal bovine
serum (Greiner), 4 mM Glutamax (Invitrogen), penicillin (100 U/
mL), streptomycin (100 lg/mL) and non-essential amino acids
(1%). Cells were grown at 37˚C in a humidified atmosphere with
5% CO2. Cells were transiently transfected with siRNA (mouse
ELP3 or mouse negative control, Ambion) and/or plasmids (indi-
cated where appropriate) using Lipofectamine 2000 (Invitrogen)
according to manufacturer’s instructions, and collected 48 or 72
h after.
Protein analyses
Mouse tissue was homogenized in T-PER buffer (Thermo Fisher
Scientific) supplemented with protease inhibitors (Complete,
Roche) by mechanical disruption for 30 s (MagNA Lyser, Roche).
NSC34 cells were lysed in the same lysis buffer. To isolate pro-
tein aggregates, lysates were sonicated (five times, duty cycle
50%, level 4) (Branson, Danbury, CT) and analyzed for protein
concentration using the BSA protein assay (ThermoScientific).
Samples with equal amount of protein were centrifuged at
20 000g for 30 min at 4C. The supernatant was collected as the
soluble fraction (containing ‘soluble SOD1’) and the pellet was
washed once with 1 ml of ice-cold lysis buffer, centrifuged again
at 20 000g for 30 min at 4C. The pellet (detergent-resistant or
insoluble fraction, containing ‘insoluble SOD1’) was then resus-
pended in 5% of the original lysis volume with 2 Laemmli buf-
fer (Bio-Rad) and sonicated (three times, duty cycle 50%, level 3).
When isolation of protein aggregates was not performed,
lysates were centrifuged at 11 000g for 15 min at 4C and the
supernatants analyzed for protein concentration. For the immu-
noprecipitation assay, lysate supernatants were incubated with
anti-FLAG M2 agarose beads (Sigma) overnight at 4C. The beads
were washed five times with ice-cold PBS and the proteins were
eluted using the 3 FLAG peptide, according to the manufac-
turer’s instructions.
Samples were resolved on 10% sodium dodecyl sulfate–
polyacrylamide gel electrophoresis (SDS-PAGE) and either silver
stained (Pierce Silver Stain Kit, Thermo) or transferred to a poly-
vinyldifluoride membrane using a semi-dry blotting apparatus
(TE70XP, Hoefer, San Francisco, CA). After blocking with 5% (w/
v) low-fat milk in Tris-buffered saline (10 mmol/l Tris, 150
mmol/L NaCl, pH 7.6) for 1 h, the membranes were incubated
overnight at 4C with the primary antibody (mouse anti-FLAG
antibody, #F3165, Sigma; rabbit anti-SOD1, #ADI-SOD-100, Enzo
Life Sciences, Farmingdale, NY; mouse anti-GAPDH, #AM4300,
Ambion), washed in Tris-buffered saline 1% Tween-20 and
incubated with HRP-conjugated secondary antibody (Dako).
After incubation, membranes were washed, developed with
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enhanced chemiluminescence (ECL western blotting substrate,
Thermo Scientific) and scanned using a LAS4000 Biomolecular
imager (GE Healthcare, Uppsala, Sweden). Images were ana-
lyzed with ImageQuant TL software (GE Healthcare).
Nerve conduction studies
Mice were anesthetized with 1% isoflurane/O2 gas inhalation
and placed on a heating pad to maintain body temperature.
Nerve conduction was measured using subdermal needle elec-
trodes (Technomed Europe) and a Medelec EMG monitor
(Medelec Vickers, Sidcup, UK) compatible with Synergy software
(version 20.1.0.100). Compound muscle action potentials
(CMAPs) were measured by supramaximal stimulation (1 pulse/
s, 0.1 ms stimulus duration), the stimulating electrode was
placed at the sciatic notch and the recording electrode at the
level of the gastrocnemius muscle. Sensory nerve action poten-
tials (SNAPs) were measured by supramaximal stimulation (6
pulse/s, 0.1 ms stimulus duration) at the distal tip of the tail and
were measured 4 cm proximal in the tail. For SNAP recordings,
multiple traces were averaged (43).
Human samples
Samples were collected after obtaining informed consent from all
human subjects. All experiments on human material were
approved by the Ethical Committee of University Hospital Leuven,
the London–Camberwell St. Giles Research Ethics Committee and
the Institutional Review Board (IRB) of Harvard University.
Statistical analysis
Statistics were performed using Graphpad prism 7.01 software
(Graphad Software, San Diego, CA) or RStudio (RStudio Team,
Boston, MA). Survival and disease onset were analyzed using
the log-rank test. Zebrafish aberrant branching were analyzed
using logistic regression. Two-way ANOVA was used for neuron
and NMJ innervation counts. Zebrafish axonal lengths, mRNA
expression levels, protein expression levels and mcm5s2U levels
were analyzed by one-way ANOVA. Significance level was
defined at 0.05. For multiple comparisons, Tukey’s post-hoc cor-
rection was applied. Error bars in graphs are S.E.M. (or mean
with 95% confidence interval for affected embryos) of at least 3
independent experiments.
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